Published in Gene Therapy Weekly, April 14th, 2005
Through the license agreement with Chiron, Kaken has obtained the rights to develop, manufacture and sell bFGF products on a worldwide basis, having previously obtained rights to bFGF in Japan and other Asian countries.
Kaken has been conducting research and development on regenerative medicine using recombinant human bFGF for more than a decade, resulting in the success of the commercialization of a wound-healing drug Fiblast Spray in 2001. Kaken is also proceeding with clinical study on periodontitis and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.